Identification of a biologically coherent three gene immune signature predictive of immunotherapy benefit in gastric adenocarcinoma

This three-gene IRGPI provides a compact, biologically anchored risk stratification signal in GAC and is associated with computationally inferred immune contexture and therapy-related signatures. These associations are hypothesis-generating and require validation in treatment-annotated cohorts, particularly gastric cancer patients receiving immune checkpoint inhibitors; robustness to alternative gene-selection strategies should also be evaluated in future work.